Ivermectin, COVID-19, infectious disease, pulmonary infection, respiratory failure
In March 2020, the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik to continuously review the rapidly emerging basic science, translational, and clinical data to develop a treatment protocol for COVID-19. The FLCCC recently discovered that ivermectin, an anti-parasitic medicine, has highly potent anti-viral and anti-inflammatory properties against SARS-CoV-2 and COVID-19. This conclusion is based on the increasing study results reporting effectiveness, not only within in-vitro and animal models, but in numerous clinical trials
Front-Line Covid-19 Critical Care Alliance.
Memphis VA Medical Center - Univ. of Tennessee Health Science Center, Memphis, TN. Hackensack School of Medicine, Seton Hall, NJ.
University of Texas Health Science Center, Houston, TX.
Center for Balanced Health, New York
Recovery Without Walls
Volda Hospital, Volda, Norway
Princess Elizabeth Hospital, Guernsey, UK
Lung Center of America, Dayton, Ohio
Review of the Emerging Evidence Supporting the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
[FLCCC Alliance; updated Dec. 18, 2020] 2 / 33
from around the world. Repeated, consistent, large magnitude improvements in clinical outcomes are reported when ivermectin is both as a prophylactic agent and in all phases of the disease from multiple, large, randomized and observational controlled trials. Further, data showing impacts on population wide health outcomes have resulted from multiple large “natural experiments” that appear to have occurred when various regional health ministries and governmental authorities within South American countries initiated “ivermectin distribution” campaigns to their citizen populations in the hopes the drug would prove effective. The tight, reproducible, temporally associated decreases in case counts and case fatality rates in each of those regions compared to nearby regions without such campaigns, suggest that ivermectin may prove to be a global solution to the pandemic. To our knowledge, the current review is the earliest to compile sufficient clinical data to demonstrate the strong signal of therapeutic efficacy as it is based on numerous clinical trials in multiple disease phases. One limitation is that half the controlled trials have been published in peer-reviewed
publications, with the remainder of the controlled trials results taken from manuscripts uploaded to medicine pre-print servers. Although it is now standard practice for trials data from pre-print servers to immediately influence therapeutic practices during the pandemic, given the controversial therapeutics adopted as a result of this practice, the FLCCC argues that it is imperative that our major national and international health care agencies devote the necessary resources to more quickly validate these studies and confirm the major, positive epidemiological impacts that have been recorded when ivermectin is widely distributed among populations with a high incidence of COVID-19 infections.